Skip to Main content Skip to Navigation
Book sections

Targeting DOT1L for mixed-lineage rearranged leukemia

Abstract : Histone methyltransferases are potential therapeutic targets for human diseases, in particular cancer. Among them, DOT1L is a lysine histone methyltransferase (KHMT) that catalyzes the methylation of lysine 79 on histone 3. Structurally, its catalytic domain is distinguished by the presence of a seven-stranded β-sheet motif, common to arginine histone methyltransferases, making it a unique KHMT. In addition to this unicity, which makes it a very interesting therapeutic target from a medicinal chemistry point of view, DOT1L plays a major role in mixed-lineage rearranged leukemia, an important subset of acute leukemia with very poor overall survival rate. Here, after an introduction to DOT1L and its role in MLL-r leukemia, we discuss the development of DOT1L inhibitors for the treatment of MLL-r and the assays used to discover and evaluate the inhibitors.
Complete list of metadata
Contributor : Marie-Ange Garnier Connect in order to contact the contributor
Submitted on : Wednesday, November 24, 2021 - 10:58:04 PM
Last modification on : Friday, August 5, 2022 - 12:02:37 PM
Long-term archiving on: : Friday, February 25, 2022 - 8:17:17 PM


Files produced by the author(s)




Corentin Bon, Yang Si, Paola B Arimondo. Targeting DOT1L for mixed-lineage rearranged leukemia. Histone Modifications in Therapy, 20, Elsevier, pp.81-99, 2020, Translational Epigenetics, 978-0-12-816422-8. ⟨10.1016/B978-0-12-816422-8.00005-2⟩. ⟨pasteur-03414682⟩



Record views


Files downloads